Information message

In order to see all the search results and access content, you must log in. Please use the Log-in button at the top of the page.

Displaying 433 - 441 of 441
Viral Hepatitis
EASL Studio Podcast: Midday Talks: HBV and HDV drug development - Where do we stand and where are we going? - 23 June 2022

EASL Studio Podcast: Midday Talks: HBV and HDV drug development - Where do we stand and where are we going? - 23 June 2022

Podcasts
View
Metabolism, Alcohol & Toxicity
EASL Studio Podcast: Midday Talks: NAFLD Roundtable - Towards effective interventions in NAFLD - 22 June 2022

EASL Studio Podcast: Midday Talks: NAFLD Roundtable - Towards effective interventions in NAFLD - 22 June 2022

Podcasts
View
Metabolism, Alcohol & Toxicity
Reducing the burden of alcohol-related liver disease (ARLD)

Reducing the burden of alcohol-related liver disease (ARLD)

Infographics
View
Metabolism, Alcohol & Toxicity
Obesity and non-alcoholic fatty liver disease (NAFLD)

Obesity and non-alcoholic fatty liver disease (NAFLD)

Infographics
View
Viral Hepatitis
Eliminating hepatitis C

Eliminating hepatitis C

Infographics
View
COVID-19 and the liver
EASL-WHO COVID-19 & the Liver

EASL-WHO COVID-19 & the Liver

On-demand Webinars
View
COVID-19 and the liver
Viral markers and the diagnosis of COVID-19

Viral markers and the diagnosis of COVID-19

Webcasts
View
COVID-19 and the liver
Viral testing and the immune response to COVID-19

Viral testing and the immune response to COVID-19

Webcasts
View
Liver Tumours
EASL Patient Synergies Roundtable Discussion: Improving the Lives of Liver Cancer Patients

EASL Patient Synergies Roundtable Discussion: Improving the Lives of Liver Cancer Patients

Webcasts
View
Displaying 433 - 441 of 441